{"article_link": "https://doi.org/10.1038/s41467-023-42565-z", "data": [{"id": "data_1", "omics": "Epigenomics", "link": "https://ngdc.cncb.ac.cn/gsa-human/", "format": "BAM", "source": "Genome Sequence Archive for Human (GSA-human)", "public_id": "HRA002815"}, {"id": "data_2", "omics": "Transcriptomics", "link": "https://ngdc.cncb.ac.cn/gsa-human/", "format": "BAM", "source": "Genome Sequence Archive for Human (GSA-human)", "public_id": "HRA000119"}, {"id": "data_3", "omics": "Genomics", "link": "https://ngdc.cncb.ac.cn/gsa-human/", "format": "VCF", "source": "Genome Sequence Archive for Human (GSA-human)", "public_id": "HRA005668"}, {"id": "data_4", "omics": "Chromatin Immunoprecipitation Sequencing (ChIP-seq)", "link": "https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE122989", "format": "BAM", "source": "Gene Expression Omnibus (GEO)", "public_id": "GSE122989"}, {"id": "data_5", "omics": "Chromatin Immunoprecipitation Sequencing (ChIP-seq)", "link": "https://ega-archive.org/", "format": "BAM", "source": "European Genome-phenome Archive (EGA)", "public_id": "EGAD00001002421"}, {"id": "data_6", "omics": "Transcriptomics", "link": "https://depmap.org/portal/download", "format": "BAM", "source": "DepMap", "public_id": "DepMap Public 21Q1"}, {"id": "data_7", "omics": "Drug Response", "link": "https://depmap.org/portal/download", "format": "TSV", "source": "DepMap", "public_id": "Drug sensitivity AUC (CTD^2)"}, {"id": "data_8", "omics": "Genomics", "link": "https://gdc.cancer.gov/about-data/publications#/?groups=TARGET-ALL-P2&years=&order=desc", "format": "VCF", "source": "TARGET", "public_id": "phs000464"}], "analyses": [{"id": "analysis_1", "analysis_type": "chromatin accessibility profiling", "analysis_data": ["data_1"], "training_set": null, "test_set": null, "label": null}, {"id": "analysis_2", "analysis_type": "comparison with B-cell progenitors", "analysis_data": ["data_1", "data_4"], "training_set": null, "test_set": null, "label": null}, {"id": "analysis_3", "analysis_type": "subtyping based on chromatin accessibility", "analysis_data": ["data_1"], "training_set": null, "test_set": null, "label": null}, {"id": "analysis_4", "analysis_type": "allele-specific open chromatin analysis", "analysis_data": ["data_1", "data_3"], "training_set": null, "test_set": null, "label": null}, {"id": "analysis_5", "analysis_type": "differential analysis", "analysis_data": ["data_1"], "training_set": null, "test_set": null, "label": null}, {"id": "analysis_6", "analysis_type": "survival analysis", "analysis_data": ["data_1", "data_8"], "training_set": null, "test_set": null, "label": null}, {"id": "analysis_7", "analysis_type": "ACR-to-gene association", "analysis_data": ["data_1", "data_2"], "training_set": null, "test_set": null, "label": null}, {"id": "analysis_8", "analysis_type": "enrichment analysis", "analysis_data": ["data_6", "data_7"], "training_set": null, "test_set": null, "label": null}, {"id": "analysis_9", "analysis_type": "motif analysis", "analysis_data": ["data_1", "data_2"], "training_set": null, "test_set": null, "label": null}, {"id": "analysis_10", "analysis_type": "survival analysis", "analysis_data": ["data_1", "data_8"], "training_set": null, "test_set": null, "label": null}], "results": [{"analysis_id": "analysis_1", "metric": "count", "value": "138,366 (median), ranging from 57,941 to 204,563", "features": ["ACRs in Quies regions", "ACRs in Enh regions", "ACRs in TssA regions", "ACRs in Tx regions"]}, {"analysis_id": "analysis_2", "metric": "overlap", "value": "98.57% (pre-pro B cells), 98.35% (pro B cells)", "features": ["IL7R", "TCL1A", "TCF3", "RHOA", "ELL", "MYC"]}, {"analysis_id": "analysis_3", "metric": "count", "value": "17,981 subtype-specific ACRs identified", "features": ["ETV6::RUNX1", "TCF3::PBX1", "Hyperdiploidy", "KMT2A", "BCR::ABL1", "BCR::ABL1-like", "ZNF384", "PAX5alt", "TCF3::HLF", "Hypodiploidy", "MEF2D", "B-other"]}, {"analysis_id": "analysis_4", "metric": "percentage", "value": "14.39% (median), significantly less than BiOC regions (85.61%)", "features": ["rs7090445", "rs13401811", "ARID5B", "BCL2L11", "MECOM", "HOXA9"]}, {"analysis_id": "analysis_5", "metric": "count", "value": "5911 relapse-high ACRs (0.95%), 1423 relapse-low ACRs (0.23%)", "features": ["Cyclophosphamide", "Cytarabine", "Dasatinib", "Dexamethasone", "Doxorubicin", "Etoposide", "Imatinib", "Methotrexate"]}, {"analysis_id": "analysis_6", "metric": "percentage", "value": "1.54% (relapse-high ACRs), 0.14% (relapse-low ACRs) shared between subtypes", "features": ["ETV6::RUNX1", "Hyperdiploidy", "KMT2A", "BCR::ABL1", "BCR::ABL1-like", "TCF3::PBX1"]}, {"analysis_id": "analysis_7", "metric": "count", "value": "116,307 ACR-gene correlations identified", "features": ["1259 potential target genes", "CDH1", "ITGB1", "ITGA1", "integrin signaling pathway", "cell adhesion pathway"]}, {"analysis_id": "analysis_8", "metric": "enrichment_score", "value": "Significant enrichment for Imatinib (p = 0.0029), Etoposide (p = 0.0184), Dasatinib (p = 0.0178), Doxorubicin (p = 0.0167)", "features": ["Imatinib", "Etoposide", "Dasatinib", "Doxorubicin"]}, {"analysis_id": "analysis_9", "metric": "count", "value": "109 TFs associated with subtype-specific ACRs", "features": ["E2F6", "RUNX1", "ZFP82", "SPI1", "KLF9", "NRF1", "RARG", "SALL4", "CTCF"]}, {"analysis_id": "analysis_10", "metric": "survival_difference", "value": "Significant differences in EFS and OS between clusters (p = 0.0012 and p = 0.0002 respectively)", "features": ["Cluster 3 (worst prognosis)", "Hyperdiploidy cases in Group B", "ETV6::RUNX1", "KMT2A", "BCR::ABL1-like"]}]}